ANCA-associated vasculitis presents the physician with a set of challenging and non-ideal therapeutic options. ANCA-associated vasculitides that are refractory to conventional therapy (namely, cyclophosphamide induction) are next best treated with rituximab (an anti-CD20 antibody). This randomized control trial now addresses the effectiveness of rituximab therapy as a first line agent in the treatment of ANCA-associated vasculitides.

***(Note: Only registered users can read and contribute to the discussion). Click here to register.

***See related teaching resources:
1. Induction Therapy for ANCA-associated vasculitis: Pulse vs. Intravenous Cyclophosphamide
2. ANCA-associated vasculitis: A review


Time Required (estimated): 20 minutes
Title: Rituximab versus Cyclophosphamide in ANCA-associated Renal Vasculitis
Citation: NEJM 2010, Volume 363, pp. 211-20
Date Created: 2010
Revisions: None Indicated
Disclaimers: Cambridge University Hospitals National Health Service Foundation Trust and F. Hoffman-La Roche (see p. 212)
Resource Type: Text


Recommend to a Colleague/Friend


Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription